Pfizer (PFE) EBITDA (2009 - 2026)

Pfizer has disclosed EBITDA across 18 years of filings, most recently posting -$6.7 billion for Q1 2026.

• In Q1 2026, EBITDA fell 0.98% year-over-year to -$6.7 billion; the TTM figure through Mar 2026 stood at -$17.7 billion (down 83.68% YoY), while the FY2025 annual figure was $20.7 billion, up 156.03% from the prior year.
• EBITDA slipped to -$6.7 billion in Q1 2026, from $4.2 billion in the prior quarter.
• Over the last five years, EBITDA for PFE reached as high as $13.0 billion in Q3 2022 and fell as low as -$13.8 billion in Q4 2023.
• The 5-year median for EBITDA is -$6.6 billion (2025), against an average of -$2.2 billion.
• Annual changes were most pronounced in 2024 — EBITDA soared 177.08% — and 2025, when it slumped 397.16%.
• A 5-year view of EBITDA shows it stood at $10.3 billion in 2022, then sank by 227.15% to -$13.1 billion in 2023, then gained by 16.28% to -$11.0 billion in 2024, then jumped by 137.82% to $4.2 billion in 2025, then tumbled by 261.62% to -$6.7 billion in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$6.7 billion, $4.2 billion, and -$7.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.